Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autogene Cevumeran + Nivolumab in High-risk Muscle-invasive Urothelial Carcinoma
NCT06534983Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Dec 2024
- Primary completion
- Nov 2027
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 15
01
Overview
A Phase 2 trial of autogene cevumeran in urothelial carcinoma (UC), sponsored by Roche. Started Dec 2024; status: active, not recruiting.
02
Drugs
autogene cevumeran
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06534983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06534983.